By Dr Stefan Walzer, expert trainer of The AI for Pharma Market Access Course
AI is beginning to change how pharma teams handle pricing, HTA submissions, and reimbursement planning. However, using it effectively requires the right tools and a clear understanding of the risks and limitations.
This compact guide introduces practical AI tools, prompt strategies, and key compliance considerations for professionals working in market access.
✅ How AI supports market access tasks
Get an overview of common use cases where AI supports tasks such as literature review, code identification, trial evaluation, dossier drafting, and payer engagement preparation.
✅ AI and the EU Joint Clinical Assessment
Understand why JCA makes AI a core part of evidence planning, and how AI supports PICO simulation and consistent dossiers.
✅ How to use prompts more effectively
See examples of structured prompts that help guide AI tools in specific tasks like evidence extraction, pricing comparisons, and HTA documentation.
✅ How to build your own AI agent
Learn the four design levers and a simple test loop to build a reliable AI agent without coding.
✅ Ethical and regulatory essentials
Understand the most relevant compliance considerations, including data privacy, transparency, and the use of AI in regulated environments.
📝 This guide offers a starting point. For deeper application and expert instruction, we recommend our full training course.
Want to take this guide with you?
Download the AI Market Access Playbook below 👇
AI is already supporting many core activities across the market access lifecycle. Below is a practical overview of the key functions AI tools are being used for, whether embedded in platforms or built with large language models and domain-specific algorithms.
| Use Case | Application in Market Access |
|---|---|
| Code Look-Up & Classification | AI helps identify relevant ICD, procedure, and outpatient codes, improving alignment with payer systems. |
| Trial Acceptability Prediction | Algorithms can score clinical trials from a payer’s perspective, helping teams adjust study design early. |
| Systematic Literature Review (SLR) | AI assists with keyword suggestion, abstract screening, full-text filtering, and evidence extraction. |
| Evidence Summarisation | Automatically creates structured summaries from clinical studies, economic models, and RWE sources. |
| Bias Detection & Quality Assessment | Supports critical appraisal of studies, identifying methodological gaps and flagging low-quality evidence. |
| Health Economic Modelling Assistance | AI can support model structuring, parameter generation, and comparisons, often via LLMs or Python+API. Agent-based platforms now also automate evidence retrieval, parameter extraction and model construction, with experts keeping final control. |
| HTA Dossier Drafting | Automates initial text creation, especially for literature sections and clinical justifications. |
| Formatting & Localisation | Assists with structuring content according to HTA body requirements and adapting for regional submissions. |
| Objection Handling Preparation | Simulates payer objections and prepares structured responses for negotiation and Q&A readiness. |
| Visualisation & Reporting | Converts extracted evidence into charts, tables, and scenario analyses to enhance communication clarity. |
⚠️ Note: These AI use cases are not a full replacement for expert review or regulatory compliance. Instead, they serve as productivity boosters, helping teams work faster and more consistently - particularly when paired with proper human oversight.
💡 Pro Tip: For sensitive or unpublished data, always use secure GPTs hosted within the EU, with encryption and no external training or data sharing. Avoid public tools for anything involving internal or regulatory content.
💡 Pro Tip: When working with AI in a regulatory setting, always document where automation was used, ensure outputs are validated by domain experts, and confirm that tools meet data security standards (e.g. no external training, EU-hosted infrastructure).
Since January 2025, the EU HTA Regulation (EU 2021/2282) requires a Joint Clinical Assessment (JCA) for new oncology medicines and ATMPs. Orphan medicines follow from January 2028, and all other new medicines from 2030. The JCA conclusions on relative clinical effectiveness are binding for national HTA bodies. Pricing, reimbursement and economic evaluation remain national.
Why this matters for AI:
One clinical evidence core is reused across all EU submissions, so errors, weak endpoints or poor comparator choices scale across Europe.
Manual dossier development does not scale to JCA timelines.
AI can simulate likely PICO scenarios early and help avoid misalignment during scoping.
Structured evidence repositories and modular dossiers keep the EU file and the national files consistent.
💡 Pro Tip: Start PICO simulation before the scoping phase. The earlier you test likely comparators and subgroups, the less rework you face later.
The quality of your prompt directly affects the accuracy and usefulness of AI outputs. Follow these practical tips to reduce errors, improve relevance, and align results with regulatory and scientific expectations:
Instruct the AI to only use the uploaded references and not access any other sources.
Prompt the GPT or AI tool you use to write with scientific accuracy and objectivity.
Be very clear and precise about what the AI should focus on (e.g. endpoints, comparators, outcomes).
Avoid vague or polite language, it reduces the precision of the response.
❌ Avoid vague prompts like: “Can you help me write a dossier?”
Always define the task, specify data sources, and indicate the intended audience or region specifically and in detail.
You don’t need coding skills to build a simple AI agent for a market access task. Free tools such as ChatGPT (GPT Builder or Custom Instructions) and Claude (Projects) are enough to start. Define four design levers in your instructions:
Persona: Who is the agent? (e.g. “a senior HTA methodologist”)
Task scope: What does it do, and what does it not do?
Output format: How should it structure every answer?
Guardrails: What must it refuse or flag? (e.g. “If data is insufficient, say so. Never invent.”)
Then improve it in a loop: draft, test, red-team (actively try to break it), refine. Plan for at least three cycles.
Example uses: interpreting G-BA benefit assessments, simulating a payer negotiator, running a gap analysis on a dossier section, drafting a value narrative.
⚠ Note: Free tools are for practice with public data only. Never paste confidential or unpublished data into them.
As AI becomes more integrated into market access workflows, ethical and regulatory responsibility must remain a top priority. GenAI offers real benefits in terms of efficiency and insight but without proper safeguards, it also poses risks related to data privacy, bias, and compliance.
Below are core principles to guide the responsible use of AI in pharma market access:
Use encrypted systems and environments not using your data for training purposes to process sensitive data.
Avoid uploading protected health information to commercial LLMs. Only use safe GPTs which are ideally closed-systems.
Recognise that complete de-identification cannot fully eliminate re-identification risk.
Prefer federated learning or differential privacy when applicable.
Follow GDPR, the EU AI Act, and (if applicable) evolving EMA, NICE, IQWiG, and other institution’s guidance.
Monitor the legal status of AI tools and ensure compliance before integrating them into HTA, pricing, or reimbursement workflows.
Also follow EFPIA’s AI principles and the ISPOR working group recommendations (first report 2025). The FDA’s internal AI tool ELSA is an early signal of how regulators themselves will use AI.
Document where and how AI is used (e.g. in literature reviews, health economic modelling, or dossier writing)
Be prepared to justify AI-generated outputs to internal and external stakeholders. Hence, critically review, adjust and approve AI-generated content.
Make sure every AI output can be traced back to its original data source.
Use version control for evidence and assumptions.
Remember that HTA bodies do not accept black-box outputs. Human-in-the-loop validation is mandatory.
Never rely on AI-generated content alone for regulatory or payer-facing submissions.
Ensure that all outputs are reviewed by qualified experts to validate relevance, accuracy, and appropriateness in context.
Use AI to assist, not replace, human judgement.
Be aware that foundation models can reinforce systemic bias if underlying data lacks representation.
When using GenAI to model populations or treatment effects, evaluate whether data inputs reflect diversity across demographics and geographies.
Implement fairness checks where feasible, especially in pricing or clinical justification outputs.
Rapid AI development requires ongoing collaboration between pharma companies and regulators.
Align internal processes with external expectations from the start.
This framework reflects emerging consensus across agencies and industry experts, but it’s only a starting point. Ethical use of AI in pharma access will require continuous adaptation, internal governance, and transparent dialogue across all stakeholders.
Where to start with AI
|

This guide is only the beginning…
Continue your learning from Stefan
If you’d like to learn more from Stefan, CELforPharma also offers a 2-day, hands-on course where you'll:
Don’t miss the latest insights from our expert faculty
Subscribe to our newsletter to: